Search Results
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings
More news about: AbbVie
Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
ORR and confirmed per investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and the secondary endpoints include DOR, DCR, PFS, OS, intracranial efficacy by RANO-BM criteria, PK and safety. About Zipalertinib
More news about: Taiho Oncology
Oct 08, 2025, 09:00 ET Vistina, a Subsidiary of Hoplon Capital, and HPS Investment Partners Announce Collaboration to Expand Asset-Based Financing Origination to Borrowers
investment-grade asset-based financing solutions to corporate borrowers," said Scott Kapnick, Chairman of the Blackrock Private Financing Solutions (PFS) Executive Office and Chief Executive Officer of HPS. "This engagement reflects HPS's focus on utilizing its ability to provide borrowers with bespoke
More news about: Hoplon Capital
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
including all 10 with CR or sCR. Median time to MRD negativity was 29 days (IQR 29-29). Median duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were not reached. The data cutoff for all analyses was December 9, 2024. About
More news about: CARsgen Therapeutics
Oct 07, 2025, 08:00 ET ARIS MINING DELIVERS 25% PRODUCTION GROWTH IN Q3 2025
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 06, 2025, 23:00 ET DEFENSE METALS PROVIDES BUSINESS UPDATE
Following the release of the Pre-Feasibility Study ("PFS") for the Wicheeda project in May 2025 (see company NR dated April 7, 2025), the Company has been working towards commencing a Definitive Feasibility Study ("DFS") in the first half of 2026. The PFS, prepared in compliance with National Instrument
More news about: Defense Metals Corp.
Oct 06, 2025, 06:30 ET Thesis Gold Drills 89.3 Metres of 1.10 Grams per Tonne Gold to Extend Mineralization at the Bingo Zone
exists within this established economic framework. Updated project economics are expected in Q4 2025 with the results of a Prefeasibility Study (the 2025 PFS) led by Ausenco Engineering Canada ULC. Highlights
More news about: Thesis Gold Inc.
Oct 02, 2025, 18:37 ET FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
offers a new way to manage this aggressive disease and gives patients and their physicians a new treatment option with the potential to increase both PFS and OS. We're proud to advance the standard of care for ES-SCLC and we continue to pursue opportunities in cancer research that improve lives."
More news about: Jazz Pharmaceuticals plc
Oct 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
Bosaya™ 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso™ 120 mg/1.7 mL (70 mg/mL injection for subcutaneous use in a single-dose vial, are biosimilars to Amgen's Prolia® and Xgeva®, respectively.
More news about: Biocon Biologics
Sep 29, 2025, 14:37 ET ARIS MINING COMPLETES SALE OF JUBY GOLD PROJECT
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 29, 2025, 07:00 ET Blue Sky Uranium Launches Exploration Program after Completing Ivana Deposit Infill Drilling Program and Advances towards Prefeasibility Study at Amarillo Grande Project, Argentina
completed the previously announced infill drilling program at the Ivana Deposit, marking a key milestone towards completing a prefeasibility study ("PFS"). The infill program included 4,959 metres of drilling across 328 holes, bringing the total drilling at the deposit to 15,839 metres of drilling
More news about: Blue Sky Uranium Corp.
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
by 38% versus ET. Among patients with ESR1-mutated MBC, Inluriyo significantly improved progression-free survival (PFS) versus fulvestrant or exemestane, with a median PFS of 5.5 months vs 3.8 months (HR=0.62 [95% CI: 0.46-0.82]); p-value=0.0008. Inluriyo is a treatment for ER+, HER2–,
More news about: Eli Lilly and Company
Sep 25, 2025, 09:37 ET The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
after at least one anthracycline- or taxane-containing chemotherapy regimen. The phase III study data showed that UTD1 plus capecitabine achieved both PFS and OS benefits versus capecitabine for heavily pretreated MBC patients, and the results were orally presented twice at ASCO annual meetings and published
More news about: Biostar Pharma, Inc.
Sep 24, 2025, 13:38 ET ARIS MINING REPORTS SAFE RECOVERY OF ALL WORKERS AT SEGOVIA PARTNER MINE
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 24, 2025, 06:15 ET Uranium Energy Corp Files Fiscal 2025 Annual Report
Commenced: Metallurgical test work significantly advanced, bulk solvent extraction and yellowcake precipitation completed and initiated a pre-feasibility study ("PFS") for the world-class, high-grade Roughrider project in Saskatchewan, Canada, in the prolific Athabasca
More news about: Uranium Energy Corp
Sep 23, 2025, 13:26 ET ARIS MINING CONFIRMS INCIDENT AT AN EXTERNAL MINE PARTNER OPERATION AT SEGOVIA
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the Blinded Independent Central Review (BICR) compared with T-DM1. Currently, Kelun-Biotech has initiated an open, multi-center
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 22:56 ET Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation
study, HARMONi-6, met its primary endpoint of progression-free survival (PFS), as confirmed by the Independent Data Monitoring Committee (IDMC). The results showed statistically significant and clinically meaningful improvements in PFS for ivonescimab plus chemotherapy compared to tislelizumab plus chemotherapy.
More news about: Akeso, Inc.
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
its primary endpoint of progression-free survival (PFS) according to the Blinded Independent Review Committee (BIRC) and its key secondary endpoint of time to next intervention (TTNI) at the second pre-specified interim analysis. The primary endpoint, PFS per BIRC, was statistically significant and clinically
More news about: Servier Pharmaceuticals
Sep 18, 2025, 21:39 ET 2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
CAR-T–naïve patients, ORR and CR/sCR rates were 98.9% and 88.4%, respectively. Among 109 patients who received Eque-cel, the median progression-free survival (PFS) was 30.5 months, extending to 35.9 months in CAR-T–naïve patients. Median overall survival (OS) was not reached. Minimal residual disease (MRD) negativity
More news about: IASO Bio
Sep 17, 2025, 07:32 ET Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
Food and Drug Administration (FDA) has approved Bosaya™ (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS), and Aukelso™ (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia® and Xgeva® respectively.
More news about: Biocon Biologics
Sep 15, 2025, 20:57 ET NEW PACIFIC FILES FORM 40-F ANNUAL REPORT
Company; inferred, indicated or measured mineral resources or mineral reserves on the Company's projects, including, but not limited to, the Silver Sand PFS Technical Report; the Carangas PEA Technical Report; the timing of receipt of permits and regulatory approvals; and estimates of the Company's revenues
More news about: New Pacific Metals Corp.
Sep 15, 2025, 08:00 ET Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
part plans to enroll 700 subjects across multiple countries/regions. The primary endpoint is overall survival (OS), with secondary endpoints including PFS, ORR, and safety. About NCT07044349 Study This study is a multi-national, open-label, randomized Phase II/III clinical trial of
More news about: Biostar Pharma, Inc.